Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,007 stopped studies mapped to B-Cell Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,007 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Phase 1 | terminated | Sep 26, 2016 | MEI Pharma, Inc. | discontinuation of zandelisib program | Other (stated, no rule matched) |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | Phase 1 | terminated | Mar 3, 2015 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT03999658 | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected… | Phase 2 | withdrawn | Jun 27, 2019 | Sorrento Therapeutics, Inc. | Sorrento Therapeutics filed for chapter 11 bankruptcy. | Other (stated, no rule matched) |
| NCT04348006 | Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple…(MM) | Phase 4 | withdrawn | Apr 15, 2020 | Al-Rasheed University College | No patients were enrolled in the study | Enrollment / accrual |
| NCT05393999 | SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2…(SABRE) | Phase 2 | withdrawn | May 27, 2022 | Imperial College Healthcare NHS Trust | The drug was found to be ineffective against Omicron, so the study was terminated and no patients… | Enrollment / accrual |
| NCT05431179 | A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell… | Phase 3 | withdrawn | Jun 24, 2022 | Oncternal Therapeutics, Inc | Due to a strategic reprioritization based on the rapidly changing clinical and commercial landscape… | Sponsor / business decision |
| NCT03371420 | PET Imaging of Subjects Using 124I-PU-AD | Early Phase 1 | terminated | Dec 13, 2017 | Samus Therapeutics, Inc. | Company has ceased operations | Sponsor / business decision |
| NCT03465540 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected… | Phase 1 | terminated | Mar 14, 2018 | Amgen | Strategic decisions | Sponsor / business decision |
| NCT04045028 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics… | Phase 1 | terminated | Aug 5, 2019 | Genentech, Inc. | Slow recruitment | Enrollment / accrual |
| NCT03411031 | Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on… | Phase 2 | terminated | Jan 25, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Sponsor no longer providing drug | Other (stated, no rule matched) |
| NCT01899326 | Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With… | N/A | terminated | Jul 15, 2013 | Albert Einstein College of Medicine | The study was stopped during the interim analysis due to low accrual after the widespread use of… | Efficacy / futility |
| NCT04075721 | First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in… | Phase 1 | terminated | Sep 3, 2019 | EMD Serono Research & Development Institute, Inc. | The study was early discontinued due to lack of participant enrollment. | Enrollment / accrual |
| NCT04635735 | Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory… | Phase 1 / Phase 2 | terminated | Nov 19, 2020 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT04521335 | Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple…(Repurpose-1) | Phase 1 | terminated | Aug 20, 2020 | University of Utah | Closed at PI's Request | Other (stated, no rule matched) |
| NCT03639610 | PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM…(BRIDGE) | Phase 2 | terminated | Aug 21, 2018 | Oncopeptides AB | The sponsor decided to terminate the study following an FDA request of a partial clinical hold. | Sponsor / business decision |
| NCT03445663 | Study Evaluating AMG 424 in Subjects With Multiple Myeloma | Phase 1 | terminated | Feb 26, 2018 | Xencor, Inc. | Previous sponsor business decision not to proceed with the AMG 424 asset. | Sponsor / business decision |
| NCT04895410 | Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV)… | Phase 1 | terminated | May 20, 2021 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04236141 | A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With… | Phase 3 | terminated | Jan 22, 2020 | Hoffmann-La Roche | Sponsor's decision, no safety concerns | Safety / toxicity |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | Phase 1 | withdrawn | Aug 24, 2022 | Shanghai Pudong Hospital | The study is not initiated and we want it to be withdrawn. | Other (stated, no rule matched) |
| NCT03370185 | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic…(BRIO) | Phase 2 | withdrawn | Dec 12, 2017 | SecuraBio | Reassessing corporate priorities. | Other (stated, no rule matched) |
| NCT02292225 | Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi… | Phase 1 | terminated | Nov 17, 2014 | SecuraBio | The scope of the program has been reduced to focus resources on studies which can potentially… | Other (stated, no rule matched) |
| NCT02807454 | A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and…(FUSIONMM-003) | Phase 2 | terminated | Jun 21, 2016 | Celgene | Health Authority request due to class effect | Other (stated, no rule matched) |
| NCT05176691 | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL | Phase 1 | withdrawn | Jan 4, 2022 | Hutchmed | HUTCHMED has decided to discontinue the HMPL 760 study. | Other (stated, no rule matched) |
| NCT03123393 | TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | terminated | Apr 21, 2017 | Calithera Biosciences, Inc | Lack of efficacy of the drug; no safety concern | Safety / toxicity |
| NCT03876028 | Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell… | Phase 1 | terminated | Mar 15, 2019 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT02077959 | Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple… | Phase 1 | terminated | Mar 4, 2014 | Ohio State University Comprehensive Cancer Center | Pharmaceutical Companies decision | Other (stated, no rule matched) |
| NCT05408026 | Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM | Phase 1 / Phase 2 | withdrawn | Jun 7, 2022 | Alliance Foundation Trials, LLC. | Study withdrawn, trial therapy deemed no longer novel and there was a lack of site interest. | Other (stated, no rule matched) |
| NCT05493618 | Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. | Phase 1 / Phase 2 | withdrawn | Aug 9, 2022 | Hackensack Meridian Health | Study Drug Unavailability | Other (stated, no rule matched) |
| NCT02389543 | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory…(SLAM) | Phase 1 / Phase 2 | withdrawn | Mar 17, 2015 | Karyopharm Therapeutics Inc | Terminated this trial and added a Lenalidomide arm to KCP-330-017 | Other (stated, no rule matched) |
| NCT02628704 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone…(SCORE) | Phase 2 | withdrawn | Dec 11, 2015 | Karyopharm Therapeutics Inc | not stated | Not stated |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT05228249 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for… | Phase 1 | withdrawn | Feb 8, 2022 | Fred Hutchinson Cancer Center | PI left institution and funding sponsor closed study. Study did not open to accrual, and no… | Investigator |
| NCT01838369 | A Phase II Study of BI-505 in Smoldering Multiple Myeloma | Phase 2 | terminated | Apr 24, 2013 | BioInvent International AB | Sponsor's decision | Sponsor / business decision |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies -… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | Incyte Corporation | not stated | Not stated |
| NCT00096460 | Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent… | Phase 2 / Phase 3 | terminated | Nov 10, 2004 | Medical College of Wisconsin | lower than anticipated accrual | Enrollment / accrual |
| NCT00995059 | Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma | Phase 1 / Phase 2 | withdrawn | Oct 14, 2009 | Mayo Clinic | not stated | Not stated |
| NCT03481556 | Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in…(ANCHOR) | Phase 1 / Phase 2 | terminated | Mar 29, 2018 | Oncopeptides AB | The sponsor decided to terminate the study following an FDA request of a partial clinical hold. | Sponsor / business decision |
| NCT04223661 | Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction… | Phase 2 | withdrawn | Jan 10, 2020 | Attaya Suvannasankha | lack of funding | Funding |
| NCT04782609 | Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma(Glio) | Phase 1 | terminated | Mar 4, 2021 | Samus Therapeutics, Inc. | Samus Therapeutics Company Closure | Sponsor / business decision |
| NCT04984330 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease(STARR) | Early Phase 1 | withdrawn | Jul 30, 2021 | Weill Medical College of Cornell University | Funding withdrawn | Funding |
| NCT01881789 | Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to… | Phase 1 / Phase 2 | terminated | Jun 20, 2013 | Amgen | A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of… | Safety / toxicity |
| NCT01416428 | Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic… | Phase 1 / Phase 2 | terminated | Aug 15, 2011 | Amgen | A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of… | Safety / toxicity |
| NCT04504708 | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant… | Phase 1 / Phase 2 | terminated | Aug 7, 2020 | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | Study terminated early due to business decision. | Sponsor / business decision |
| NCT02716805 | Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell… | Phase 1 | terminated | Mar 23, 2016 | Ludwig Institute for Cancer Research | FDA placed on partial hold due to additional data | Other (stated, no rule matched) |
| NCT02618109 | Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute…(LABMI) | Phase 4 | terminated | Dec 1, 2015 | University Hospital, Angers | recruitment difficulties | Enrollment / accrual |
| NCT04635683 | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory… | Phase 1 | withdrawn | Nov 19, 2020 | Yazeed Sawalha | Investigational Drug removed from the market | Other (stated, no rule matched) |
| NCT02225275 | Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic… | Phase 2 | terminated | Aug 26, 2014 | M.D. Anderson Cancer Center | Due to slow accrual | Enrollment / accrual |
| NCT02531308 | Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)(DLBCL) | Phase 2 | terminated | Aug 24, 2015 | Rush University Medical Center | poor accrual | Enrollment / accrual |
| NCT04998747 | A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple…(ProxiMMity-1) | Phase 1 | withdrawn | Aug 10, 2021 | Amgen | Amgen Decision to stop development of AMG 701 SC, not for safety reasons but for business reasons. | Safety / toxicity |
| NCT04746131 | Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed… | Phase 1 | suspended | Feb 9, 2021 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Due to the product development strategy change, without any safety concerns, we (the sponsor of the… | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 9, 2023source: clinicaltrials